Biomarkers in Neuropsychiatry最新文献

{"title":"Whole-body hyperthermia as a novel antidepressant therapy","authors":"Kevin D. Gaitonde ,&nbsp;Henry A. Nasrallah","doi":"10.1016/j.bionps.2025.100124","DOIUrl":"10.1016/j.bionps.2025.100124","url":null,"abstract":"<div><div>First-line treatments for major depressive disorder include medication and cognitive behavioral therapy. While effective, pharmacotherapy often takes time to start demonstrating efficacy in symptomatic improvement and may be accompanied by adverse effects, indicating an ongoing need for new therapeutic approaches. A recently emerging somatic antidepressant intervention is whole-body hyperthermia, in which subjects are temporarily exposed to heat and then allowed to cool down. Recent studies employing hyperthermia-based strategies appear to show mood improvements both immediately and several weeks after the conclusion of treatment. However, published studies are often limited by their sample sizes and by their selection criteria. In this article, we review the literature on this novel approach and propose ideas regarding the possible physiological basis of this novel intervention and how it may be used in the future as adjunctive therapy with the current standard of care.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GABA dysfunction in schizophrenia: The GABAA receptor as a potential therapeutic target","authors":"Brandon L.M. Crotchett,&nbsp;Seth D. Reighard,&nbsp;Henry A. Nasrallah","doi":"10.1016/j.bionps.2025.100130","DOIUrl":"10.1016/j.bionps.2025.100130","url":null,"abstract":"<div><div>Schizophrenia is a complex psychiatric disorder characterized by debilitating positive, negative, and cognitive symptoms, whose etiology is traditionally attributed to dopamine dysregulation. While dopamine receptor antagonists effectively alleviate positive symptoms, they fail to address the persistent cognitive and negative symptom domains of disease. Growing evidence supports a broader neurobiological framework in which cortical excitation-inhibition (E/I) imbalance acts as an upstream contributor to dopaminergic dysregulation in schizophrenia, with the neurotransmitters gamma-aminobutyric acid (GABA) and glutamate playing a critical role in this homeostasis. Herein, we summarize such evidence, including preclinical findings from animal models of schizophrenia that support the role of GABAergic dysfunction in disease pathophysiology and validate the GABA_A receptor as a promising therapeutic target. We review the potential of subtype-selective GABA_A receptor modulators to restore E/I balance and improve symptoms currently resistant to antidopaminergic agents. Key challenges and considerations for the future development of these therapeutics are also discussed, emphasizing the importance of targeting E/I imbalance to better understand and treat the network-level dysfunction underlying schizophrenia.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPA system in anxiety disorder patients treated with cognitive behavioural therapy: A review","authors":"Jennifer Lange ,&nbsp;Angelika Erhardt-Lehmann","doi":"10.1016/j.bionps.2024.100116","DOIUrl":"10.1016/j.bionps.2024.100116","url":null,"abstract":"<div><div>Anxiety disorders (AD) have a complex etiology involving genetic, psychophysiological and environmental factors. Recent biomarker research in AD shows alterations in anatomical, biochemical and physiological pathways as well as in endocrinological processes. Perceived stress is one of the factors often reported in relation to the onset and the course of AD. Hence, the function of the hypothalamus-pituitary-adrenal (HPA) axis, the endogenous system regulating the stress response homeostasis, may serve as biomarker in disease etiology and response to treatment. Vice versa, successful treatment could have an advantageous effect on the function of the HPA system. In the present review, we summarize findings on the HPA system in relation to AD and first results on its modifiability in response to cognitive behavioral therapy (CBT), one of the most efficacious psychotherapeutic treatments for AD. We specifically focus on findings of experimental studies that explored cortisol levels before, during and after exposure-based CBT. A systematic search was conducted in MEDLINE/PubMed, PsycINFO, Web of Science, and in references of retrieved studies until April 2024. The inclusion criteria were studies enclosing keywords related to the HPA axis, an anxiety disorder and CBT techniques. The results of the summarized studies suggest that cortisol levels have the potential to indicate the AD disease status and serve as possible biomarker in outcome prediction. Global dysfunction of the HPA system seems to point to higher symptom burden and less advantageous response to CBT. Furthermore, low cortisol levels elicited in relation to exposure interventions are repeatedly associated with risk for non-response. Additionally, some evidence suggests that successful CBT containing exposure sessions as well as cognitive techniques induces normalization of the HPA system by reducing acute response to fear related stimuli in parallel to normalizing basal cortisol levels. To conclude, cortisol seems to be a promising candidate to depict several aspects of AD-related disease status and CBT effects, however, additional prospective studies are needed to evaluate the mode of applications of this marker in the clinical routine.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subjective experience, psychosocial functioning and different psychomotor clusters in catatonia: How are they connected?","authors":"Geva A. Brandt ,&nbsp;Stefan Fritze ,&nbsp;Dilsa Cemre Akkoc Altinok ,&nbsp;Sebastian Volkmer ,&nbsp;Jacqueline Kukovic ,&nbsp;Jonas Daub ,&nbsp;Katharina M. Kubera ,&nbsp;Georg Northoff ,&nbsp;Andreas Meyer-Lindenberg ,&nbsp;Dusan Hirjak","doi":"10.1016/j.bionps.2024.100113","DOIUrl":"10.1016/j.bionps.2024.100113","url":null,"abstract":"<div><h3>Background</h3><div>Catatonia involves decreased, increased, and abnormal psychomotor activity, but most previous studies mainly focused on motor signs, neglecting the patients' subjective experiences. This study aimed to characterize psychomotor activity levels as introduced in the ICD-11 and their relation to subjectivity and overall psychosocial functioning in catatonia.</div></div><div><h3>Methods</h3><div>We examined 54 patients with catatonia and 90 patients with schizophrenia spectrum- or mood disorders according to ICD-11 using an extensive battery of psychomotor-related clinical rating scales and Northoff Scale for subjective experience in catatonia (NSSC). For catatonia patients partial correlation coefficients between ICD-11 psychomotor clusters and their surrogate parameters were calculated. Group differences were analyzed using MANCOVA and post-hoc ANOVA. Finally, linear discriminant analysis (LDA) was used to examine the classification value of the respective rating scales and different surrogate parameters of ICD-11-related psychomotor activity.</div></div><div><h3>Results</h3><div>In catatonia patients decreased psychomotor activity was associated with psychomotor retardation (p&lt;.05)), while increased activity was positively correlated with impulsivity and negatively correlated with psychomotor retardation (both p-values&lt;.01). Abnormal psychomotor activity was positively associated with stereotypies as well as mannerisms, affectation and posturing. Significant group differences were observed in subjective experience, social performance, trait anxiety, psychomotor slowing, processing speed, and cognitive functioning. LDA revealed that the respective psychomotor-related rating scales are capable of distinguishing between diagnostic groups, albeit with varying degrees of classification accuracy (61.8 %-87.5 %).</div></div><div><h3>Conclusion</h3><div>We identified a relationship between varying levels of psychomotor activity, subjective experiences, and psychosocial functioning in catatonia as defined by the ICD-11. Future large-scale studies are needed to validate these findings and refine assessment tools, such as the NSSC, by integrating subjective experiences with objective rating scales. This approach could pave the way for more tailored treatment options that consider the unique subjective experiences of catatonia patients.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive performance and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT) - 2","authors":"Brett A. Clementz ,&nbsp;Ishanu Chattopadhyay ,&nbsp;S. Kristian Hill ,&nbsp;Jennifer E. McDowell ,&nbsp;Sarah K. Keedy ,&nbsp;David A. Parker ,&nbsp;Rebekah L. Trotti ,&nbsp;Elena I. Ivleva ,&nbsp;Matcheri S. Keshavan ,&nbsp;Elliot S. Gershon ,&nbsp;Godfrey D. Pearlson ,&nbsp;Carol A. Tamminga ,&nbsp;Robert D. Gibbons","doi":"10.1016/j.bionps.2024.100117","DOIUrl":"10.1016/j.bionps.2024.100117","url":null,"abstract":"<div><h3>Objective</h3><div>The B-SNIP consortium validated neurobiologically defined psychosis Biotypes (BT1, BT2, BT3) using cognitive and psychophysiological measures. B-SNIP’s biomarker panel is not practical for most settings. Previously, B-SNIP developed an efficient classifier of Biotypes using only clinical assessments (called ADEPT-CLIN) with acceptable accuracy (∼.81). Adding cognitive performance may improve ADEPT’s performance.</div></div><div><h3>Method</h3><div>Clinical assessments from ADEPT-CLIN plus 18 cognitive measures from 1907 individuals with a B-SNIP psychosis Biotype were used to create an additional diagnostic algorithm called ADEPT-COG. Extremely randomized trees were used to create this low burden classifier.</div></div><div><h3>Results</h3><div>Total Biotype classification accuracy peaked at 94.6 % with 65 items. A reduced set of 18 items showed 90.5 % accuracy. Only 9–10 items achieved a one-vs-all (e.g., BT1 or not) accuracy of ∼.95, considerably better than using clinical assessments alone. The top discriminators of psychosis Biotypes were antisaccade proportion correct, BACS total, symbol coding, antisaccade correct response latency, verbal memory, digit sequencing, stop signal reaction times, stop signal proportion correct, Tower of London, and WRAT Reading. Except for antisaccade proportion correct and Tower of London, there was no overlap of the top discriminating items for B-SNIP Biotypes and DSM psychosis categories.</div></div><div><h3>Conclusions</h3><div>This low-burden algorithm using clinical and cognitive measures achieved high classification accuracy and can support Biotype-specific etiological and treatment investigations in clinical and research environments. It may be especially useful for clinical trials.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers in alcohol use disorder - The promise and pitfalls of neuroimaging drug cue reactivity","authors":"Marlen Pfisterer ,&nbsp;Sina Zimmermann ,&nbsp;Judith Zaiser ,&nbsp;Sarah Gerhardt ,&nbsp;Sabine Vollstädt-Klein ,&nbsp;Falk Kiefer ,&nbsp;Patrick Bach","doi":"10.1016/j.bionps.2025.100119","DOIUrl":"10.1016/j.bionps.2025.100119","url":null,"abstract":"","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100119"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Football-related concussions and head impacts are associated with changes in retinal structure and signaling” [Biomark. Neuropsychiatry 10 (2024) 100091]","authors":"Steven M. Silverstein ,&nbsp;Jason Atlas ,&nbsp;Mia Young ,&nbsp;Lyvia Bertolace ,&nbsp;Iwona Juskiewicz ,&nbsp;Kian Merchant-Borna ,&nbsp;Sarah Dermady ,&nbsp;Yonatan Abrham ,&nbsp;Kyle Green ,&nbsp;Jeff Bazarian ,&nbsp;Rajeev S. Ramchandran ,&nbsp;Brian P. Keane","doi":"10.1016/j.bionps.2024.100118","DOIUrl":"10.1016/j.bionps.2024.100118","url":null,"abstract":"","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional perspectives on (bio)markers: Linking clinical and biological insights across psychiatric disorders, supporting a transdiagnostic model","authors":"Dusan Hirjak","doi":"10.1016/j.bionps.2025.100129","DOIUrl":"10.1016/j.bionps.2025.100129","url":null,"abstract":"<div><div>This editorial serves as an introduction to the Special Issue \"Biomarkers of Trans-Nosological Functional Domains\", offering an overview of its central themes and contributions.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding missing disclosure statements of previously published articles","authors":"","doi":"10.1016/j.bionps.2025.100127","DOIUrl":"10.1016/j.bionps.2025.100127","url":null,"abstract":"","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100127"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease","authors":"Tapas K. Sur ,&nbsp;Tanmoy Mondal ,&nbsp;Zarish Noreen ,&nbsp;Jheannelle Johnson ,&nbsp;Gail Nunlee-Bland ,&nbsp;Christopher A. Loffredo ,&nbsp;Brent E. Korba ,&nbsp;Vijay Chandra ,&nbsp;Siddhartha S. Jana ,&nbsp;Bernard Kwabi-Addo ,&nbsp;Sumit Sarkar ,&nbsp;Somiranjan Ghosh","doi":"10.1016/j.bionps.2025.100120","DOIUrl":"10.1016/j.bionps.2025.100120","url":null,"abstract":"<div><div>Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease, with no standard biomarker(s) to detect or confirm its risk at an early stage. The prevalence of AD increases exponentially worldwide in people of ages over 65 and older. Current improvements have unveiled the disease's pathophysiology and clinical diagnostic tests, targeting the neurological changes (neurodegeneration, amyloid precursor protein metabolism and tangle pathology) with precise PET/MRI imaging and xMAP/SIMOA (Multiplex simultaneous detection/single molecule array) to identify and quantify β-amyloids (Aβ40, Aβ42), total tau (T-tau) and phosphorylated tau (P-tau) proteins in the brain and cerebrospinal fluid (CSF) of patients. However, their utility for diagnosis in routine clinical practice is still challenging because of cost, accessibility, standardization, procedural limitation, and regulatory approval. Further research is needed to establish affordable, patient-friendly, easy, quick, and robust biomarkers for early AD detection, progression, and therapeutic management. Research on blood-based preclinical diagnosis and clinical practice for AD has advanced significantly in the last decade. Emerging literature supports the importance of new molecular biomarkers and signature genes from blood to detect and predict AD in advance. This review examines the potential applications of these blood-based target biomarkers for early disease detection, co-morbid condition risk prediction, and treatment management of AD.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143352413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}